BUSINESS

Kimberly Clark to acquire Kenvue creating consumer giant

Kimberly-Clark will buy Tylenol-maker Kenvue in a cash-and-stock deal valued around $48.7 billion, aiming to form one of the largest U.S. consumer health companies. Premarket trading reflected the jolt: Kenvue shares jumped 18% while Kimberly-Clark fell 12.5%. The combined portfolio, spanning Neutrogena, Huggies and Kleenex, is expected to generate roughly $32 billion in annual revenue. Kenvue, spun off from Johnson & Johnson in 2023, has been under strategic review and leadership shake-up amid mounting litigation risks and scrutiny following President Donald Trump’s comments about Tylenol. Kenvue investors will receive $3.50 plus 0.15 Kimberly-Clark shares per share.

Reviewed by JQJO team

#acquisition #merger #kimberlyclark #kenvue #shares